Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

作者：Benjamin Besse, Enriqueta Felip, Rosario García Campelo, Manuel Cobo, Céline Mascaux, Anne Madroszyk, Federico Cappuzzo, Werner Hilgers, Gianpiero Romano, Fabrice Denis, Santiago Viteri, D. Debieuvre, Domenico Galetta, Editta Baldini, M. Razaq, G. Robinet, Michele Maio, Angelo Delmonte, Benoît Roch, Patrick Masson, Wolfgang Schuette, Alona Zer, Jordi Remón, D Costantini, B. Vasseur, Rafał Dziadziuszko, Giuseppe Giaccone, Milada Zemanová, Benjamin Besse, Clément Bonnet, Jacques Cadranel, C. Chouaïd, Alexis B. Cortot, D. Debieuvre, B. Delclaux, Fabrice Denis, Boris Duchemann, Claude El Kouri, François‐Régis Ferrand, M. Ginoux, Werner Hilgers, Anne Madroszyk, Patrick Masson, Julien Mazières, O. Molinier, Denis Moro‐Sibilot, Éric Pichon, Céline Mascaux, G. Robinet, Benoît Roch, Gérard Zalcman, Gerlinde Schmidtke-Schrezenmeier, Wolfgang Schuette, László Urbán, Maya Gottfried, Hovav Nechushtan, Nir Peled, M. Wollner, Alona Zer, Editta Baldini, Laura Bonanno, Andrea Bonetti, Federico Cappuzzo, Angelo Delmonte, Domenico Galetta, Michele Maio, V. Minotti, Antonio Rea, Gianpiero Romano, Davide Tassinari, Giuseppe Tonini, Rafał Dziadziuszko, Bogusława Karaszewska, Aleksandra Szczęsna, Manuel Cobo, J. De Castro, Enriqueta Felip, M.R. García Campelo, Ainhoa Hernández, Teresa Morán, Mariano Provencio, Santiago Viteri, Abhijit Dasgupta, Nashat Gabrail, Giuseppe Giaccone, A. Harshad, Stephen V. Liu, D. Oubre, Rajiv Panikkar, M. Razaq, Rachel E. Sanborn · 发表于：Annals of Oncology · 年份：2023 · DOI：10.1016/j.annonc.2023.07.006 · 被引用次数：72 · 研究领域：Cancer Immunotherapy and Biomarkers、Cancer, Stress, Anesthesia, and Immune Response、Immunotherapy and Immune Responses

BACKGROUND: Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients. PATIENTS AND METHODS: ATALANTE-1 was a two-step open-label study to evaluate the efficacy and safety of OSE2101 compared to standard-of-care (SoC) chemotherapy (CT). Patients with human leukocyte antigen (HLA)-A2-positive advanced NSCLC without actionable alterations, failing sequential or concurrent CT and ICB were randomized (2 : 1) to OSE2101 or SoC (docetaxel or pemetrexed). Primary endpoint was overall survival (OS). Interim OS futility analysis was planned as per Fleming design. In April 2020 at the time of interim analysis, a decision was taken to prematurely stop the accrual due to coronavirus disease 2019 (COVID-19). Final analysis was carried out in all patients and in the subgroup of patients with ICB secondary resistance defined as failure after ICB monotherapy second line ≥12 weeks. RESULTS: Two hundred and nineteen patients were randomized (139 OSE2101, 80 SoC); 118 had secondary resistance to sequential ICB. Overall, median OS non-significantly favored OSE2101 over SoC {hazard ratio (HR) [95% confidence interval (CI)] 0.86 [0.62-1.19], P = 0.36}. In the secondary...